Applied Therapeutics, Inc.

NasdaqCM:APLT Stock Report

Market Cap: US$15.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Applied Therapeutics Management

Management criteria checks 1/4

Applied Therapeutics' CEO is Les Funtleyder, appointed in Nov 2023, has a tenure of 2.25 years. total yearly compensation is $1.05M, comprised of 50.4% salary and 49.6% bonuses, including company stock and options. directly owns 0.33% of the company’s shares, worth $51.70K. The average tenure of the management team and the board of directors is 1.5 years and 7.9 years respectively.

Key information

Les Funtleyder

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage50.35%
CEO tenure2.3yrs
CEO ownership0.3%
Management average tenure1.5yrs
Board average tenure7.9yrs

Recent management updates

Recent updates

Analysis Article • Jul 15

Here's Why Applied Therapeutics (NASDAQ:APLT) Must Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Nov 15

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Applied...
Seeking Alpha • Sep 18

Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review

Summary FDA removes the need for an advisory panel to first give a recommendation review of Applied Therapeutics, Inc.'s govorestat for the treatment of patients with galactosemia. PDUFA date of November 28th, 2024, remains on track for the FDA to decide whether govorestat should be approved to treat patients with galactosemia. Pre-NDA meeting with FDA expected in 2nd half of 2024 to discuss possible administrative actions of NDA filing submission of govorestat for the treatment of patients with SORD deficiency. If the pre-NDA meeting of govorestat for SORD deficiency goes well, then the company would be in a good position to file an NDA for this drug in Q1 of 2025. Read the full article on Seeking Alpha
Seeking Alpha • Sep 04

Applied Therapeutics: Pushing Towards FDA Approval

Summary Today, we revisit clinical stage developmental concern Applied Therapeutics, Inc. for the first time in 2024. The company is moving towards its first FDA approval before yearend, and could garner another approval for a different indication in 2025. An updated analysis around Applied Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Analysis Article • Aug 01

We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Applied...
Seeking Alpha • May 28

Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases

Summary Applied Therapeutics develops govorestat for rare diseases and AT-001 for diabetic cardiomyopathy; both are aldose reductase inhibitors. Govorestat shows promise as a treatment for galactosemia by preventing galactose conversion. AT-001’s efficacy in diabetic cardiomyopathy is inconclusive; significant results are only in certain subgroups. Hold APLT stock due to high risks despite potential in niche markets; it's suitable for a diversified high-risk portfolio segment. Read the full article on Seeking Alpha
Seeking Alpha • Feb 16

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Summary Positive 12-month interim results from the phase 3 INSPIRE study using govorestat for the treatment of patients with SORD deficiency achieved. Pre-NDA meeting with FDA to be sought out after to see if an NDA submission of govorestat for SORD deficiency could be done with only the positive 12-month interim data. 24-month interim results from the phase 3 INSPIRE study, using govorestat for the treatment of patients with SORD deficiency, is the next data readout to be expected. The NDA of govorestat for galactosemia has been submitted by the FDA and the EMA has validated the MAA; There is a good chance that Applied Therapeutics could receive regulatory approval for one or both of these territories. Read the full article on Seeking Alpha
Analysis Article • Feb 16

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. Indeed, Applied Therapeutics...
Analysis Article • Nov 13

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Applied Therapeutics...
Analysis Article • Aug 11

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • May 19

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jan 19

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Applied Therapeutics shares were hammered this month after FDA did not agree to accelerated approval for its drug candidate AT-007 in treating galactosemia in children. Investors and sell-side analysts are completely discounting the potential of the pipeline. Even in a conservative scenario, shares could reach $165 by 2028 or 38x upside potential. I provide various scenarios and my calculations on revenue potential, and enterprise value potential.
Analysis Article • Nov 11

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Aug 13

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • May 15

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Feb 26

Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

Investors who take an interest in Applied Therapeutics, Inc. ( NASDAQ:APLT ) should definitely note that the...

CEO Compensation Analysis

How has Les Funtleyder's remuneration changed compared to Applied Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$18m

Jun 30 2025n/an/a

-US$68m

Mar 31 2025n/an/a

-US$44m

Dec 31 2024US$1mUS$531k

-US$106m

Sep 30 2024n/an/a

-US$187m

Jun 30 2024n/an/a

-US$161m

Mar 31 2024n/an/a

-US$194m

Dec 31 2023US$675kn/a

-US$120m

Sep 30 2023n/an/a

-US$97m

Jun 30 2023n/an/a

-US$73m

Mar 31 2023n/an/a

-US$70m

Dec 31 2022US$80kn/a

-US$83m

Sep 30 2022n/an/a

-US$95m

Jun 30 2022n/an/a

-US$105m

Mar 31 2022n/an/a

-US$105m

Dec 31 2021US$229kn/a

-US$106m

Sep 30 2021n/an/a

-US$102m

Jun 30 2021n/an/a

-US$104m

Mar 31 2021n/an/a

-US$106m

Dec 31 2020US$303kn/a

-US$94m

Sep 30 2020n/an/a

-US$88m

Jun 30 2020n/an/a

-US$69m

Mar 31 2020n/an/a

-US$49m

Dec 31 2019US$625kn/a

-US$46m

Compensation vs Market: Les's total compensation ($USD1.05M) is above average for companies of similar size in the US market ($USD574.54K).

Compensation vs Earnings: Les's compensation has increased whilst the company is unprofitable.

CEO

Les Funtleyder (55 yo)

2.3yrs
Tenure
US$1,053,846
Compensation

Mr. Les D. Funtleyder has been an Independent Director of Reviva Pharmaceuticals Holdings, Inc. since December 8, 2020. Mr. Funtleyder served as Interm CEO, CFO, Principal Financial Officer & Independent D...

Leadership Team

NamePositionTenureCompensationOwnership
Les Funtleyder
Interm CEO2.3yrsUS$1.05m0.33%
$ 51.7k
Corwin Hooks
Chief Commercial Officer1.8yrsUS$2.18m0.053%
$ 8.4k
Constantine Chinoporos
COO & Chief Business Officer2.2yrsno data0.051%
$ 8.0k
Catherine Thorpe
Interim Chief Accounting Officer2.7yrsno datano data
Reena Colacot
Head of Quality1.1yrsno datano data
Todd Baumgartner
Chief Regulatory Officerless than a yearno datano data
Evan Bailey
Chief Medical Officerless than a yearno data0.36%
$ 55.7k
Dottie Caplan
Executive Vice President of Patient Advocacy & Government Affairs.less than a yearno datano data
1.5yrs
Average Tenure
58.5yo
Average Age

Experienced Management: APLT's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Les Funtleyder
Interm CEO9.7yrsUS$1.05m0.33%
$ 51.7k
Jay Skyler
Independent Director6.8yrsUS$267.50k0.035%
$ 5.5k
Lawrence Steinman
Member of Scientific Advisory Boardno datano datano data
Teena Lerner
Lead Independent Director8.9yrsUS$265.00k0.069%
$ 10.8k
Stacy Kanter
Independent Director6.8yrsUS$267.50k0.035%
$ 5.5k
Gregg Stone
Member of Scientific Advisory Boardno datano datano data
Donald Landry
Chairman of Scientific Advisory Boardno datano datano data
Donald D'Amico
Member of Scientific Advisory Boardno datano datano data
Roy Freeman
Member of Scientific Advisory Boardno datano datano data
Roxana Mehran
Member of Scientific Advisory Boardno datano datano data
7.9yrs
Average Tenure
69yo
Average Age

Experienced Board: APLT's board of directors are considered experienced (7.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/02 19:23
End of Day Share Price 2026/02/02 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Applied Therapeutics, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Carter GouldBarclays
Paul ChoiGoldman Sachs
Luke DavisRBC Capital Markets